Last reviewed: May 12, 2026
Last updated: September 22, 2026
Written by: Jay Hastings, CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by: Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Director, with a PharmD and MBA specializing in pharmacogenomics and clinical product development. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies and weight-management care. Browse all Peptides & GLP-1 education
Editorial note: PlexusDx publishes this editorial review and offers one of the programs discussed. PlexusDx is not affiliated with MEDVi and has no commercial relationship with the companies named in this article; there are no affiliate links. Information is based on the sources and dates shown.
As of September 22, 2026, MEDVi's program page does not list branded Mounjaro®. MEDVi's branded options are Wegovy® pill, Wegovy® injection, and Zepbound® injection, offered as a $99 monthly membership plus the medication cost (as listed on MEDVi’s program page, September 22, 2026), with availability marked "subject to change." MEDVi's core program dispenses compounded tirzepatide, which shares the active ingredient with Mounjaro® and Zepbound® but is not the branded product and is not FDA-approved. MEDVi's ongoing month-to-month rate for compounded tirzepatide injection is $399, verified September 22, 2026; MEDVi shows its tirzepatide first-month offer after the questionnaire, so confirm it in the official offer.
Is branded Mounjaro currently available through MEDVi?
Not on the published menu. MEDVi's program page shows two pathways. The compounded pathway lists semaglutide injection, tirzepatide injection, and a compounded GLP-1 tablet, with medication included in the program price and "no membership or hidden fees," as MEDVi describes it. The branded pathway lists Wegovy® pill, Wegovy® injection, and Zepbound® injection at a monthly membership fee plus the medication cost, billed separately. Mounjaro® does not appear in either list. Because MEDVi marks branded availability as subject to change, ask directly if Mounjaro® matters to you, and remember that whether any branded product is prescribed is a decision for the licensed provider in MEDVi's network, not the platform.
Mounjaro, Zepbound, and compounded tirzepatide
These are three different products with one active ingredient. Mounjaro® and Zepbound® are FDA-approved tirzepatide products made by Eli Lilly and Company, the only U.S. company with FDA-approved tirzepatide. Mounjaro® is labeled for adults with type 2 diabetes; Zepbound® is labeled for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Which label applies to you is a clinical question.
Compounded tirzepatide is prepared by a state-licensed 503A compounding pharmacy for an individual prescription. It is not FDA-approved, is not reviewed by FDA for quality, safety, or efficacy, and is not a generic or equivalent version of Mounjaro® or Zepbound®. Results from the branded drugs' clinical trials do not establish outcomes for a compounded injection or oral formulation. A licensed pharmacy and a licensed prescriber are not FDA approval of the product. The FDA's statement on unapproved GLP-1 drugs explains these distinctions. Do not treat "Mounjaro" as a label for a compounded product, and be cautious of any listing that does.
PlexusDx publishes this comparison and offers one of the programs discussed. Information is based on the sources and dates shown.
| Product |
What it is |
FDA status |
Through MEDVi? |
Cost basis (checked Sept 22, 2026) |
| Mounjaro® (tirzepatide) |
Eli Lilly branded injection, type 2 diabetes label |
FDA-approved |
Not listed on MEDVi's page |
Not offered by MEDVi; no MEDVi price |
| Zepbound® (tirzepatide) |
Eli Lilly branded injection, weight-management and OSA labels |
FDA-approved |
Yes, branded pathway (availability subject to change) |
Monthly membership + medication cost, billed separately |
| Compounded tirzepatide injection (MEDVi) |
Pharmacy-prepared for an individual Rx |
Not FDA-approved |
Yes, core program |
$399 per cycle ongoing month-to-month (MEDVi's rate, verified September 22, 2026); first-month offer shown after the questionnaire — confirm in MEDVi's official offer |
| Compounded Tirzepatide Injection (PlexusDx) |
Pharmacy-prepared for an individual Rx |
Not FDA-approved |
Not applicable (PlexusDx program) |
$289/mo month-to-month, flat across doses |
Checked September 22, 2026 on MEDVi's program page and PlexusDx's product page. MEDVi's branded membership figure is shown on its page; the medication cost is billed separately and is not published as a fixed amount. Compounded and branded rows are different products and are not price-equivalent.
View PlexusDx tirzepatide plans
PlexusDx Tirzepatide Injection is $289/mo month-to-month, all-inclusive (provider visit, prescription, compounded medication, shipping). No membership fee. Flat price at every dose. 3- and 6-month plans are also published.
View PlexusDx tirzepatide plans → Start my PlexusDx intake →
Membership and medication costs
MEDVi's branded pathway has two charges: a monthly membership fee and the medication itself, which MEDVi bills separately at whatever the branded product costs through its channel. MEDVi's compounded pathway has one charge that includes the medication: MEDVi's ongoing month-to-month rate for compounded tirzepatide injection is $399, verified September 22, 2026, with the first-month offer shown after the questionnaire. For reference, Eli Lilly's own self-pay channel lists Zepbound® single-dose vials at $299 per month for 2.5 mg, $399 per month for 5 mg, and $449 per month for 7.5 mg through 15 mg under its self-pay program as of September 22, 2026, with regular prices higher if a refill falls outside the program window; these are LillyDirect prices, not MEDVi prices.
PlexusDx Tirzepatide Injection (compounded) is $289 per month month-to-month, versus MEDVi's ongoing $399 per month for compounded tirzepatide injection (verified September 22, 2026), $110 a month less at PlexusDx, or $3,468 versus $4,788 over 12 billing cycles at the ongoing rates; PlexusDx also lists $269 per month on a 3-month plan or $249 per month on a 6-month plan, and the price is flat across every dose level. One monthly price covers the provider visit, prescription, medication, and shipping, with no membership fee and $0 charged until your provider approves. PlexusDx does not offer branded Mounjaro® or Zepbound®. Cost shoppers comparing tirzepatide programs should use MEDVi Tirzepatide Cost: First Month, Refills, and Plan Options; the branded route is covered in MEDVi Zepbound: Branded Access, Membership, and Medication Cost and MEDVi Wegovy and Zepbound Costs: Membership Plus Medication.
Where PlexusDx fits
If your question is really "how do I get tirzepatide without a membership fee," PlexusDx's compounded Tirzepatide Injection at $289 per month is the comparable option, prescribed by an independent network of U.S.-licensed clinicians through a state-licensed telehealth platform. See all PlexusDx weight-management plans.
Questions for the prescribing clinician
Whatever program you consider, the prescriber decides what, if anything, is appropriate. Useful questions: Which product would you prescribe for me, branded or compounded, and why? Which FDA label, if any, applies to my situation? If compounded, which pharmacy prepares it and what does that mean for oversight? How will you monitor me, and how do I reach you about side effects? Is a video visit required in my state? How does the price change, if at all, when my dose changes? Bring the answers to any cost comparison, because a lower price on a different product is not a like-for-like saving.
Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company; Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. PlexusDx is not affiliated with or endorsed by either company.
A note on genetics (optional)
PlexusDx offers compounded semaglutide and tirzepatide through its Weight Management Protocols. Separately, and only if it interests you, the GLP-1 & Peptide Pathways Genetic Test ($298) analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, MC4R and TCF7L2 that relate to appetite and glucose-handling pathways. It does not predict how you will respond to any medication and does not tell you which drug, dose or provider is right for you; it is context for a conversation with your clinician. Test before you invest, and treat genetics as a guide, not a guarantee.
This article is educational. PlexusDx is not affiliated with MEDVi and has no commercial relationship with the companies discussed. PlexusDx offers compounded semaglutide and tirzepatide through its own Weight Management Protocols; this article compares approaches in the GLP-1 telehealth space. The GLP-1 & Peptide Pathways Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not predict response to any specific medication and does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol. Compounded semaglutide and tirzepatide are not FDA-approved drug products; they are prepared by state-licensed compounding pharmacies under federal compounding rules and are not the same as Wegovy®, Ozempic®, Zepbound® or Mounjaro®. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company; Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. PlexusDx is not affiliated with or endorsed by either company.
Frequently Asked Questions
Does MEDVi offer branded Mounjaro?
Not on its published menu as of September 22, 2026. MEDVi's program page lists Wegovy® pill, Wegovy® injection, and Zepbound® injection on its branded pathway, priced as a monthly membership plus the medication cost, and marks availability as subject to change. Its core program dispenses compounded tirzepatide, which is not Mounjaro®. Whether any product is prescribed is the provider's decision.
Is MEDVi's compounded tirzepatide the same as Mounjaro?
No. Compounded tirzepatide shares the active ingredient but is prepared by a state-licensed compounding pharmacy for an individual prescription. It is not FDA-approved, is not reviewed by FDA for quality, safety, or efficacy, and is not a generic or equivalent of Mounjaro® or Zepbound®. Trial results for the branded drugs do not establish outcomes for compounded formulations.
What is the difference between Mounjaro and Zepbound?
Both are FDA-approved tirzepatide injections made by Eli Lilly and Company. Mounjaro® is labeled for adults with type 2 diabetes, while Zepbound® is labeled for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Which label applies to you, and whether either product is appropriate, is a question for your prescribing clinician.
How much does tirzepatide cost through MEDVi?
MEDVi's ongoing month-to-month rate for compounded tirzepatide injection is $399, verified September 22, 2026; MEDVi shows its tirzepatide first-month offer after the questionnaire, so confirm that figure in its official offer. Branded Zepbound® through MEDVi is a monthly membership plus the medication cost, billed separately. For comparison, PlexusDx compounded Tirzepatide Injection is $289 per month month-to-month with no membership fee, $110 a month less than MEDVi's ongoing rate.
Does PlexusDx prescribe Mounjaro or Zepbound?
No. PlexusDx offers compounded Tirzepatide Injection and Tirzepatide Oral, prepared by state-licensed 503A compounding pharmacies for an individual prescription, at $289 per month and $349 per month month-to-month respectively. Compounded products are not FDA-approved and are not the same as Mounjaro® or Zepbound®. An independent, U.S.-licensed clinician decides whether a prescription is appropriate.
Sources and dates checked
Start my PlexusDx intake
A ~60-second intake. A licensed clinician in PlexusDx’s network reviews it and independently decides whether a prescription is appropriate. No charge unless your provider approves. Compare plans first: View PlexusDx tirzepatide plans.
Start my PlexusDx intake →
This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. Sources and the dates they were checked are listed at the end of the article.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services, and offers compounded GLP-1 programs through its Weight Management Protocols. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
MEDVi Discounts: Introductory Offers, Bundles, and Real Savings
MaxLife Semaglutide: How the Telehealth Program Handles It